CMG MedSource Book a Free Call Home›Resources›GLP-1 Compounding Provider Guide GLP-1 Sourcing GLP-1 Compounding for Medical Practices: A Provider's Guide CMG MedSource September 2026 10 min read GLP-1 receptor agonists like semaglutide and tirzepatide have become central to weight management and metabolic health programs at clinics across the country. As a medical practice operator, understanding the compounding sourcing pathway, what has changed as FDA shortage designations have evolved, and what compliance steps protect your practice is essential before building a GLP-1 program. Important regulatory note: The FDA ended shortage designations for semaglutide (Ozempic/Wegovy) and tirzepatide (Mounjaro/Zepbound) in 2025. This significantly affected the legal basis for compounding these specific molecules. The information in this guide reflects the general compounding framework and historical context. Before prescribing any compounded GLP-1 medication, confirm current regulatory status with a healthcare compliance attorney. CMG MedSource can also provide current sourcing guidance based on what is available and compliant at the time of your inquiry. Background: Why Compounded GLP-1s Became Common Between 2022 and 2025, FDA-approved semaglutide and tirzepatide products were listed on the FDA's drug shortage database. Under Section 503A and 503B of the FD&C Act, compounding pharmacies and outsourcing facilities are permitted to compound copies of drugs that appear on the shortage list, allowing providers to access these medications when brand-name supply was constrained. This led to a significant expansion of GLP-1 compounding, with hundreds of 503A and 503B facilities producing compounded semaglutide and tirzepatide. The FDA's decision to remove these drugs from the shortage list in 2025 created a more complex regulatory environment, with ongoing legal and regulatory proceedings about which compounding pathways remain valid. The Two GLP-1 Compounding Pathways Patient-Specific (503A) Pathway Under the 503A pathway, a licensed prescriber writes a patient-specific prescription for compounded semaglutide or tirzepatide. The 503A pharmacy prepares the medication specifically for that patient and ships it directly to them or to a clinic for administration. For this pathway to be legal post-shortage, practitioners typically rely on specific clinical justifications for why a patient needs a compounded version rather than the commercially available branded product (such as documented patient-specific need under 503A(a)(1)). Bulk / Office Stock (503B) Pathway Under the 503B pathway, an FDA-registered outsourcing facility produces batch quantities of compounded GLP-1 medication and distributes them to licensed healthcare providers for office stock. During the shortage period, this was widely used by weight management clinics, med spas, and telehealth operators. Post-shortage, 503B facilities must operate under different authority, and availability from specific facilities has varied. The ongoing legal landscape requires providers to verify the current legal status of any 503B GLP-1 product they are considering. What Practices Need Before Starting a GLP-1 Program Clinical Infrastructure Licensed prescribers with valid state medical licenses and DEA registration An intake and evaluation protocol establishing medical appropriateness for each patient A monitoring protocol for GLP-1 side effects including nausea, gastroparesis risk, and injection site reactions Written informed consent that discloses use of a compounded (non-FDA-approved) preparation Refrigeration or storage per the compounding facility's labeled requirements Compliance Documentation Pharmacy partner's FDA registration (for 503B) or state pharmacy license (for 503A) Certificates of analysis (COAs) for each batch received, confirming sterility testing and potency Pharmacy's liability insurance and DEA registration (for Schedule III or other scheduled compounds, if applicable) Records of all orders, lot numbers, and patient administration or dispensing Patient Communication Patients should understand that compounded GLP-1 preparations are not FDA-approved and are produced by a compounding pharmacy or outsourcing facility. Informed consent documentation should reflect this clearly. Avoid making efficacy or outcome claims in patient-facing materials that go beyond what clinical evidence supports. Quality signals to look for in a pharmacy partner: PCAB accreditation (for 503A), FDA registration and CGMP compliance (for 503B), clean inspection history on FDA.gov, batch-specific COAs with sterility and potency testing, labeled beyond-use dates consistent with USP standards, and demonstrated experience supplying practices in your clinical specialty. Evaluating a Compounding Pharmacy for GLP-1 Products Not all compounding pharmacies that marketed GLP-1 products operated at the same quality standard. Due diligence before selecting a pharmacy partner should include: FDA inspection history: Search the FDA's Warning Letter database and 483 inspection observations for the facility name. Warning letters or Form 483 observations related to sterility or potency are significant red flags. PCAB accreditation: For 503A pharmacies, Pharmacy Compounding Accreditation Board (PCAB) accreditation is a meaningful quality signal. COA transparency: Reputable facilities provide batch-specific certificates of analysis showing testing for identity, potency, sterility, endotoxins, and particulate matter. Beyond-use dating: COAs should support the labeled beyond-use date, not just carry an arbitrary expiration claim. Current regulatory status: The facility should be able to articulate under what authority they are currently compounding GLP-1 products, given the changed shortage status. Frequently Asked Questions Can medical practices still prescribe compounded GLP-1 medications in 2026? The answer depends on current regulatory status and the specific compounding pathway. As of the 2025 shortage designation removal, the broad shortage-based compounding authority for semaglutide and tirzepatide was curtailed. Certain patient-specific pathways under 503A may remain available in specific circumstances. Providers should confirm current status with a healthcare compliance attorney before building or continuing a compounded GLP-1 program. Where can I get compounded GLP-1 medications for my practice? Access to compounded GLP-1 medications depends heavily on current regulatory status. During the shortage period, both 503A pharmacies and 503B outsourcing facilities supplied these medications broadly. Post-shortage, availability has narrowed. CMG MedSource can provide current guidance on what sourcing options are available and compliant at the time of your inquiry, based on our active relationships with the pharmacy community. What is the difference between compounded semaglutide and Ozempic or Wegovy? Ozempic and Wegovy are FDA-approved brand-name drug products containing semaglutide, manufactured by Novo Nordisk. Compounded semaglutide is a preparation made by a compounding pharmacy using semaglutide as an active ingredient, without FDA approval of the specific preparation. The active molecule is the same, but the manufacturing source, quality oversight, and legal status differ. What documentation should my practice maintain for GLP-1 compounding orders? Maintain records of all pharmacy orders including lot numbers, quantities, and beyond-use dates; certificates of analysis for each lot received; signed patient informed consent documents; prescribing records with clinical basis for each patient; and documentation of your pharmacy partner's licensing and compliance credentials. These records are essential in the event of a regulatory inquiry or liability claim. Does my practice need a DEA license to prescribe or stock compounded GLP-1s? Semaglutide and tirzepatide are not currently DEA-scheduled controlled substances, so a DEA registration is not required specifically for GLP-1 compounds. However, a valid DEA registration is required for any controlled substances your practice prescribes, and some pharmacy credentialing processes require it regardless. Confirm with your pharmacy partner what credentials they require for onboarding. Building a Compliant GLP-1 Sourcing Program? CMG MedSource works with weight management clinics, med spas, and telehealth operators to navigate compliant pharmaceutical sourcing. Our consultation is free for licensed providers. Book a Free 15-Minute Call Related articles: 503A vs. 503B Compounding: What Healthcare Providers Need to Know Compounded Peptide Therapy: Sourcing, Compliance, and Clinical Use What Is a Pharmaceutical Sourcing Partner and Do You Need One? Home info@cmgmedsource.com Schedule a Call CMG MedSource | Dallas, Texas | Pharmaceutical Sourcing for Licensed Providers This content is for informational purposes only and does not constitute legal or regulatory advice. Regulatory status for compounded medications changes frequently. Consult with a qualified healthcare compliance attorney for current guidance.